Back
 AID  Vol.10 No.3 , December 2020
A Physician Suffering from COVID-19 with Multiple Co-Morbidities Have Delayed Viral Clearance: A Case Report from Bangladesh
Md. Reaz Uddin Chowdhury1, Kazi Shanzida Akter2, Sahedul Islam Bhuiyan3, Md. Khalilur Rahman Khabir4, Bimal Chandra Das1, Muhammad Anwarul Kabir1
Show more
Abstract: Background: Novel corona virus (SARS-Coronavirus-2 SARS-CoV-2) which emerged in China has spread to multiple countries rapidly. Little information is known about delayed viral clearance in mild to moderate COVID-19 pa-tients. As it is highly contagious, health care workers including physicians are high risk of being infected in hospital care. Case Report: A 37 years old Bangladeshi physician working in a paediatric unit of a medical college hos-pital with multiple co-morbidities, hypertension, diagnosed axial spondy-loarthropathy (ankylosing spondylitis) taking disease modifying anti rheu-matic drugs— DMARDs (Salfasalazine) from 2016 till now, chronic persis-tent bronchial asthma on medication developed sore throat, increasing breathlessness and cough admitted to his own hospital on 22 April, 2020. He had a history of contact with a relapse nephrotic syndrome (glomerulone-phritis) patient admitted with severe respiratory distress later confirmed as COVID-19 following RT PCR test on 14 April, 2020. After 3 days of contact with the patient, the physician also developed the symptoms mentioned above. The RT PCR test result of the physician came positive on 18 April, 2020. The physician primarily taken only azithromycin 500 mg once daily along with other regular drugs. On 5, 12 and 18 May, 2020, his sample was taken for re-test and came positive subsequently. After that he started Iver-mectin (0.15 mg/kg) once daily for 3 days and doxycycline 100 mg BD for 7 days. He gave samples again on 27 and 29 May, 2020 which were came nega-tive after 39 days. On full recovery he was discharged from hospital on day 40. We choose the patient because presence of co-morbidities may be asso-ciated with delayed viral clearance and physicians with co-morbidities working in a hospital have high risk of being infected.
Keywords: Physician, Co-Morbidities, Viral Clearance, COVID-19, Case Report, Bangla-desh
Cite this paper: Chowdhury, M. , Akter, K. , Bhuiyan, S. , Khabir, M. , Das, B. and Kabir, M. (2020) A Physician Suffering from COVID-19 with Multiple Co-Morbidities Have Delayed Viral Clearance: A Case Report from Bangladesh. Advances in Infectious Diseases, 10, 94-100. doi: 10.4236/aid.2020.103009.
References

[1]   World Health Organisation (WHO) (2019) Corona Virus Disease 2019. (COVID19): Situation Report-84. WHO, Geneva.

[2]   Huang, C., Wang, Y., Li, X., et al. (2020) Clinical Feature of Patients with 2019 Novel Corona Virus in Wuhan, China. The Lancet, 395, 497-506.
https://doi.org/10.1016/S0140-6736(20)30183-5

[3]   Chen, N., Zhou, M., Dong, X., et al. (2020) Epidemiological and Clinical Characteristic of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.
https://doi.org/10.1016/S0140-6736(20)30211-7

[4]   Wang, D., Hu, B., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Corona Virus Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.
https://doi.org/10.1001/jama.2020.1585

[5]   Kui, L., Fang, Y.Y., Deng, Y., et al. (2020) Clinical Characteristics of Novel Corona Virus Cases in Tertiary Hospitals in Hubei Province. Chinese Medical Journal, 133, 1025-1031.

[6]   Chen, X.P., et al. (2020) Hypertension and Diabetes Delay the Viral Clearance in COVID19 Patients.

[7]   Carlos, W.G., Dela Cruz, C.S., Cao, B., Pasnick, S. and Jamil, S. (2020) Novel Wuhan (2019-nCoV) Coronavirus. American Journal of Respiratory and Critical Care Medicine, 201, P7-P8.
https://doi.org/10.1164/rccm.2014P7

[8]   Rothe Camilla, S.M., Peter, S., Gisela, B., et al. (2020) Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England Journal of Medicine, 382, 970-971.
https://doi.org/10.1056/NEJMc2001468

[9]   Li, J., Niu, P.H., Yang, B., et al. (2020) Genomic Characterization and Epidemiology of 2019 Novel Coronavirus Implications for Virus Origins and Receptor Bindings. The Lancet, 395, 565-574.
https://doi.org/10.1016/S0140-6736(20)30251-8

[10]   Lo, L.L., Lio, C.F., Cheong, H.H., et al. (2020) Evaluation of SARS-CoV-2 RNA Shedding in Clinical Specimens and Clinical Characteristics of 10 Patients with COVID 19 in Macau. International Journal of Biological Sciences, 16, 1698-1707.
https://doi.org/10.7150/ijbs.45357

[11]   Liu, Y., Yan, L.M., Wan, L., et al. (2020) Viral Dynamics in Mild and Severe Cases of COVID19. The Lancet Infectious Diseases, 20, 656-657.

[12]   Ling, Y., Yan, L.M., Wan, L., et al. (2020) Persistence and Clearance of Viral RNA in 2019 Novel Corona Virus Disease Rehabilitation Patients. Chinese Medical Journal, 133, 1039-1043.

[13]   Fang, L.K. and Roth, G.M. (2020) Are Patients with Hypertension and Diabetes Mellitus at Increased Risk for COVID19 Infections? The Lancet Respiratory Medicine, 8, e21.
https://doi.org/10.1016/S2213-2600(20)30116-8

[14]   Li, X.C., Zhang, J. and Zhuo, J.L. (2017) The Vasoprotective Axes of the Rennin-Angiotensin System: Physiological Relevance and Therapeutic Implications in Cardiovascular, Hypertensive and Kidney Disease. Pharmacological Research, 125, 21-38.
https://doi.org/10.1016/j.phrs.2017.06.005

[15]   D’Antiga, L. (2020) Coronaviruses and Immunosuppressed Patients. The Facts during the Third Epidemic. Liver Transplantation, 26, 832-834.
https://doi.org/10.1002/lt.25756

 
 
Top